REPL
Replimune Group, Inc. NASDAQ Listed Jul 20, 2018$3.33
After hrs
$4.09
+0.49%
Mkt Cap $275.0M
52w Low $1.50
15.6% of range
52w High $13.24
50d MA $5.57
200d MA $6.80
P/E (TTM)
-0.8x
EV/EBITDA
-3.0x
P/B
0.5x
Debt/Equity
0.2x
ROE
-119.6%
P/FCF
-3.9x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$5.57
200d MA
$6.80
Avg Volume
4.6M
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
500 Unicorn Park Drive · Woburn, MA 01801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | AMC | -0.77 | -0.77 | -0.2% | 7.38 | +1.1% | -5.1% | -6.1% | +5.0% | +5.4% | +5.7% | — |
| Nov 6, 2025 | AMC | -0.87 | -0.90 | -3.4% | 8.50 | -3.3% | -2.2% | +2.5% | +7.4% | +6.4% | +5.6% | — |
| Aug 7, 2025 | AMC | -0.83 | -0.95 | -14.5% | 5.48 | -1.6% | -3.5% | -8.9% | -4.2% | -7.1% | -2.4% | — |
| May 22, 2025 | AMC | -0.75 | -0.82 | -9.3% | 8.76 | -0.6% | -4.7% | -3.9% | -3.8% | +7.0% | +2.5% | — |
| Feb 12, 2025 | AMC | -0.70 | -0.79 | -12.9% | 13.79 | -0.7% | +3.6% | +2.2% | +1.7% | -0.1% | +3.8% | — |
| Nov 12, 2024 | AMC | -0.75 | -0.68 | +9.3% | 12.19 | -0.1% | -4.1% | -6.5% | -11.4% | -11.6% | -10.2% | — |
| Aug 8, 2024 | AMC | -0.88 | -0.78 | +11.4% | 9.45 | +0.5% | +1.4% | +1.1% | +3.0% | +4.3% | +9.0% | — |
| May 16, 2024 | AMC | -0.86 | -0.82 | +4.7% | 6.72 | +1.0% | -4.2% | -11.6% | -17.1% | -11.8% | -15.8% | — |
| Feb 8, 2024 | AMC | -0.94 | -0.77 | +18.1% | 7.72 | +5.8% | +0.5% | +3.0% | -7.3% | -11.0% | -0.8% | — |
| Nov 7, 2023 | AMC | -0.80 | -0.90 | -12.5% | 10.83 | +1.2% | +6.6% | +6.0% | +2.6% | -1.0% | +3.6% | — |
| Aug 3, 2023 | AMC | -0.85 | -0.75 | +11.8% | 19.25 | -0.5% | +2.8% | -1.6% | -5.0% | -1.5% | +1.3% | — |
| May 18, 2023 | AMC | -0.66 | -0.74 | -12.1% | 19.64 | +0.4% | -0.3% | +0.3% | -0.9% | -3.2% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | Wedbush | Downgrade | Outperform → Neutral | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Apr 13 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Apr 13 | HC Wainwright & Co. | Downgrade | Buy → Sell | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Apr 13 | Jefferies | Downgrade | Buy → Hold | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Apr 13 | JP Morgan | Downgrade | Neutral → Underweight | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Apr 13 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $4.76 | $1.71 | -64.1% | -64.3% | -59.0% | -52.1% | -54.0% | -54.4% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.00 | $7.03 | +0.4% | -1.0% | +10.7% | +11.1% | +11.4% | +10.9% |
| Feb 4 | Wedbush | Maintains | Outperform → Outperform | — | $7.38 | $7.46 | +1.1% | -5.1% | -6.1% | +5.0% | +5.4% | +5.7% |
| Nov 3 | BMO Capital | Upgrade | Underperform → Market Perform | — | $9.73 | $9.35 | -3.9% | -4.3% | -7.8% | -11.8% | -12.6% | -14.6% |
| Oct 27 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $8.80 | $9.29 | +5.6% | +6.0% | +18.8% | +16.0% | +16.5% | +10.6% |
| Oct 20 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $4.50 | $9.19 | +104.2% | +98.9% | +80.0% | +84.4% | +87.1% | +95.6% |
| Oct 20 | JP Morgan | Upgrade | Underweight → Neutral | — | $4.50 | $9.19 | +104.2% | +98.9% | +80.0% | +84.4% | +87.1% | +95.6% |
| Oct 20 | Wedbush | Upgrade | Neutral → Outperform | — | $4.50 | $9.19 | +104.2% | +98.9% | +80.0% | +84.4% | +87.1% | +95.6% |
| Sep 19 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.46 | $3.40 | -1.7% | -6.6% | -5.5% | +25.1% | +20.2% | +17.1% |
| Sep 8 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.33 | $6.24 | -1.4% | -4.6% | -8.1% | -5.4% | -5.1% | -9.5% |
| Jul 30 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $3.75 | $6.42 | +71.2% | +101.3% | +87.5% | +102.7% | +52.3% | +68.5% |
| Jul 23 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.81 | $2.74 | -2.5% | +18.9% | +10.3% | +12.1% | +12.8% | +33.5% |
| Jul 23 | Barclays | Downgrade | Overweight → Equal Weight | — | $2.81 | $2.74 | -2.5% | +18.9% | +10.3% | +12.1% | +12.8% | +33.5% |
| Jul 23 | BMO Capital | Downgrade | Outperform → Underperform | — | $2.81 | $2.74 | -2.5% | +18.9% | +10.3% | +12.1% | +12.8% | +33.5% |
| Jul 22 | Wedbush | Downgrade | Outperform → Neutral | — | $12.33 | $2.71 | -78.0% | -77.2% | -72.9% | -74.9% | -74.5% | -74.3% |
| Jul 22 | Jefferies | Maintains | Buy → Buy | — | $12.33 | $2.71 | -78.0% | -77.2% | -72.9% | -74.9% | -74.5% | -74.3% |
| Jul 22 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $12.33 | $2.71 | -78.0% | -77.2% | -72.9% | -74.9% | -74.5% | -74.3% |
| Jul 22 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.33 | $2.71 | -78.0% | -77.2% | -72.9% | -74.9% | -74.5% | -74.3% |
| Jul 16 | JP Morgan | Maintains | Overweight → Overweight | — | $12.40 | $13.19 | +6.4% | +1.9% | +0.8% | -2.5% | -0.6% | -77.3% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.55 | $9.70 | +1.6% | -1.6% | +1.0% | -2.2% | +8.8% | +12.8% |
| Jun 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.98 | $9.28 | +3.3% | +6.6% | +7.2% | +7.9% | +8.6% | +15.6% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $13.49 | $13.83 | +2.5% | -1.9% | -6.3% | -6.0% | -10.2% | -10.9% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.79 | $13.70 | -0.7% | +3.6% | +2.2% | +1.7% | -0.1% | +3.8% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.85 | $12.23 | +3.2% | +9.9% | +16.0% | +14.7% | +15.5% | +18.3% |
| Jan 22 | BMO Capital | Maintains | Outperform → Outperform | — | $11.85 | $12.23 | +3.2% | +9.9% | +16.0% | +14.7% | +15.5% | +18.3% |
| Dec 4 | Jefferies | Maintains | Buy → Buy | — | $13.14 | $13.40 | +2.0% | +0.2% | -0.7% | -0.5% | -3.8% | -2.3% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.05 | $13.68 | +23.8% | +35.1% | +20.0% | +30.1% | +27.1% | +27.4% |
| Nov 22 | BMO Capital | Maintains | Outperform → Outperform | — | $11.05 | $13.68 | +23.8% | +35.1% | +20.0% | +30.1% | +27.1% | +27.4% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.49 | -0.1% | -2.5% | -6.5% | -8.8% | -13.6% | -13.8% |
| Sep 24 | JP Morgan | Maintains | Overweight → Overweight | — | $10.96 | $11.20 | +2.2% | +1.0% | +1.0% | +1.6% | +1.8% | +0.0% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.13 | $11.23 | +0.9% | -6.0% | -0.9% | -0.4% | +0.9% | -2.0% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.53 | $10.55 | +0.2% | -1.8% | -1.5% | -1.4% | +5.7% | -0.7% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $9.55 | $9.32 | -2.4% | +1.9% | +3.2% | +7.9% | +5.9% | +7.6% |
| Jun 7 | Barclays | Maintains | Overweight → Overweight | — | $7.11 | $7.26 | +2.1% | +11.1% | +26.6% | +26.6% | +24.1% | +33.1% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.11 | $7.26 | +2.1% | +11.1% | +26.6% | +26.6% | +24.1% | +33.1% |
| Dec 6 | Barclays | Maintains | Overweight → Overweight | — | $6.75 | $6.80 | +0.7% | +9.0% | +12.6% | +8.0% | +10.4% | +9.5% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.07 | -0.4% | -3.5% | +1.0% | +0.5% | -7.1% | -6.4% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $10.83 | $10.96 | +1.2% | +6.6% | +6.0% | +2.6% | -1.0% | +3.6% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.79 | $19.92 | +0.7% | -4.2% | -7.5% | -4.2% | -1.5% | +0.8% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.07 | $21.10 | +0.1% | -2.5% | +1.2% | -8.6% | -6.1% | -10.1% |
| Jun 15 | JP Morgan | Maintains | Overweight → Overweight | — | $23.48 | $24.60 | +4.8% | +2.3% | +1.6% | +0.7% | +0.0% | +0.2% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.85 | $22.78 | -0.3% | -1.3% | -1.7% | +2.6% | +5.5% | +2.8% |
| Jun 7 | Wedbush | Maintains | Outperform → Outperform | — | $23.63 | $23.86 | +1.0% | -3.3% | -4.5% | -4.9% | -0.8% | +2.0% |
| Jun 7 | EF Hutton | Maintains | Buy → Buy | — | $23.63 | $23.86 | +1.0% | -3.3% | -4.5% | -4.9% | -0.8% | +2.0% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.99 | $20.42 | +7.5% | +19.0% | +24.4% | +20.3% | +18.8% | +18.3% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Replimune's RP1 oncolytic virus therapy failed FDA approval, dealing a significant setback to the company's pipeline and likely pressuring the stock given the treatment was a key revenue driver candidate.
Apr 13
8-K · 1.01
!! High
Replimune Group, Inc. -- 8-K 1.01: Material Agreement
Replimune secured an additional $30 million in funding from Hercules Capital through a loan amendment, providing financial flexibility for the biotech company's clinical development programs.
Feb 3
Data updated apr 26, 2026 10:28pm
· Source: massive.com